Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Interest & Investment Income (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Interest & Investment Income data on record, last reported at $236000.0 in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 61.69% year-over-year to $236000.0; the TTM value through Sep 2025 reached $1.1 million, down 64.99%, while the annual FY2024 figure was $2.6 million, 53.94% down from the prior year.
  • Interest & Investment Income reached $236000.0 in Q3 2025 per BTAI's latest filing, up from $230000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.0 million in Q1 2023 and bottomed at $15000.0 in Q1 2022.
  • Average Interest & Investment Income over 4 years is $768266.7, with a median of $671000.0 recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 13333.33% in 2023, then crashed 70.54% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $1.5 million in 2022, then tumbled by 36.41% to $945000.0 in 2023, then plummeted by 61.06% to $368000.0 in 2024, then crashed by 35.87% to $236000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $236000.0 in Q3 2025, $230000.0 in Q2 2025, and $279000.0 in Q1 2025.